American Shared Hospital Services Balances Growth And Strain

American Shared Hospital Services ((AMS)) has held its Q4 earnings call. Read on for the main highlights of the call.

American Shared Hospital Services’ latest earnings call painted a mixed picture, blending solid operational advances with serious financial strain. Management underscored strong growth in direct patient care and LINAC volumes, plus international momentum and staffing stability. Yet compressed margins, a swing to net loss, depleted cash and covenant breaches left investors facing elevated near‑term risk despite management’s long‑term optimism.

Direct Patient Care Revenue Growth

Direct Patient Care Services continued to transform the company’s revenue mix, rising 23.7% year over year to $15.5 million in fiscal 2025. These services now account for the majority of the business, representing 63% of fourth‑quarter revenue at $4.8 million, which management framed as a more scalable and resilient model than traditional equipment leasing.

LINAC Volume and Revenue Expansion

Linear accelerator, or LINAC, operations were a standout, with revenue jumping 35.4% to $11.5 million in 2025. Treatment sessions more than doubled to 28,147 on the back of the first full year of operations at the Puebla, Mexico, and Rhode Island centers, signaling strong demand and validating the company’s investment in these newer sites.

International and Center Development Progress

International units delivered robust performance, with the Puebla center exceeding expectations and Lima successfully relocated and upgraded to the Esprit Gamma Knife platform. The company also preserved its leadership positions in Ecuador and Peru, while development of the Guadalajara center remains on track to begin operations in 2026, supporting a longer‑term growth runway.

Strategic Partnerships and Contract Wins

American Shared deepened key health‑system relationships, announcing a new collaboration with Brown University Health and a seven‑year lease extension with Orlando Health for proton therapy. These partnerships are helping rebuild physician staff and lift treatment volumes in Rhode Island, providing greater visibility on future utilization and revenue streams.

Operational Improvements and Stabilized Staffing

Management highlighted progress on operational fundamentals, including stabilization of radiation oncology physician staffing in Rhode Island. Investments in revenue cycle management and technology upgrades drove same‑center Gamma Knife volume improvements, changes executives believe will gradually translate into stronger cash flow generation and margin recovery.

Quarterly Operational Profitability Metrics

Fourth‑quarter adjusted EBITDA turned positive at $868,000, underscoring improving operational execution on a quarterly basis. The net loss attributable to the company narrowed to $631,000, or $0.09 per diluted share, compared with a $1.6 million loss a year earlier, indicating that cost control and mix shifts are starting to gain traction.

Quarterly and Leasing Revenue Declines

Despite those gains, headline revenue moved the wrong way, with total fourth‑quarter revenue down 14.8% to $7.7 million from $9.1 million. Medical Equipment Leasing revenue was particularly weak, plunging 33.9% in the quarter to $2.9 million as proton volumes fell and three Gamma Knife contracts expired, and leasing revenue for the full year slipped to $12.6 million.

Proton Beam and Gamma Knife Revenue Weakness

Proton beam radiation therapy, once a key growth engine, saw revenue decline 26% to $7.4 million for the year, reflecting softer demand and operational challenges. Gamma Knife revenue also fell 5.5% to $9.2 million, weighing on overall top‑line results and reinforcing the strategic push away from a pure leasing model toward direct patient care.

Material Gross Margin Compression

Margins deteriorated sharply, with fourth‑quarter gross profit dropping to about $906,000, or 12%, versus 35% a year earlier, a 23‑point contraction that alarmed investors. For the full year, gross margin fell to $5.1 million, or 18%, from $9.2 million in 2024, a roughly 45% decline that highlights the earnings pressure created by mix shifts and under‑utilized assets.

Full-Year Profitability Swing and Lower Adjusted EBITDA

The company swung to a fiscal‑year net loss of $1.6 million, or $0.23 per diluted share, compared with $2.2 million of net income in 2024, which had benefited from a one‑time $3.8 million bargain purchase gain. Adjusted EBITDA, a key cash‑flow proxy, fell to $5.5 million from $8.9 million, a drop of about 38%, signaling that operating profitability remains under significant pressure.

Significant Cash Decline and Capital Spend

Liquidity is now a focal concern, with year‑end cash plunging to roughly $3.7 million from $11.3 million, a decline of about 67%. Management attributed the drop primarily to $7.5 million in capital expenditures tied to the Rhode Island expansion and international investments, but the thinner cash cushion heightens sensitivity to any operational setbacks.

Debt, Covenant Breach and Going Concern Risk

Total debt stood at approximately $17.3 million, and the company admitted that certain financial covenants were not met at year‑end. Executives acknowledged “substantial doubt” about the company’s ability to continue as a going concern without covenant amendments, and said lender negotiations are in progress, making balance‑sheet repair and covenant relief critical near‑term catalysts.

Revenue Stability but No Top-Line Growth

On a full‑year basis, total revenue was essentially flat at $28.1 million versus $28.3 million in 2024, revealing that top‑line growth has yet to emerge despite the strategic pivot. Management emphasized that the revenue base is becoming more stable and patient‑care driven, but investors will want to see this translate into sustained growth and improved profitability.

Governance and Capital Allocation Questions

The call also surfaced investor concerns around governance and capital allocation, including the absence of a stock repurchase program. Management pointed to lender restrictions and capital priorities, while questions about relatively low insider and board ownership underscored ongoing debate over alignment with common shareholders.

Forward-Looking Guidance and Growth Catalysts

Looking ahead, management expects 2026 to bring better treatment volumes and margin improvement as the now majority direct‑patient care platform scales, aided by strong LINAC momentum and early same‑center volume gains. Planned growth drivers include the Guadalajara center in 2026, a Bristol facility targeted for late 2027, a new proton center in 2028 and renewed flexibility from lender amendments, all against the backdrop of modest current margins and tight liquidity.

American Shared Hospital Services’ earnings call framed a company in transition, with clear operational wins but a balance sheet under pressure. For investors, the story now hinges on whether rising direct patient care volumes, expanding LINAC usage and new centers can outpace margin compression and resolve covenant risks before liquidity tightens further.